Hyloris Pharmaceuticals buys global rights to CRD-102 from Baker Institute
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is being developed for late-stage heart failure (HF) patients who have an implanted left ventricular assist device (LVAD1) and have developed right HF. According to Hyloris Pharmaceuticals, CRD-102 is the second […]